Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug
Rena Conti quoted in Bloomberg Law, January 31, 2023
Tag: Rena Conti
A banner year for prescription drugs brings cost concerns
Rena Conti quoted in Axios, January 6, 2023
Comments on the draft harmonized system code list of critical supply chains
Rena Conti’s OP-ED in Brookings Institution, November 7, 2022
Why Europe’s drug shortages may get worse
Rena Conti quoted in Reuters, February 8, 2023
US Insurer Spending on Ivermectin Prescriptions for COVID-19
Insurers heavily subsidize the cost of ivermectin prescriptions for COVID, despite the lack of evidence that ivermectin is effective for COVID. In a new paper, published in JAMA, Questrom professor and TPRI co-lead Rena Conti with colleagues Kao-Ping Chua and Nora Becker (both University of Michigan) estimate that U.S. insurers may have wasted $2.5 million on these drugs in the week of August 13, 2021 alone.
Addressing the trade-off between lower drug prices and incentives for pharmaceutical innovation
TPRI faculty co-lead and Questrom faculty Rena Conti will testify at the upcoming U.S. House of Representatives hearing of the Committee on Oversight and Reform, entitled “Unsustainable Drug Prices: Findings from the Committee’s Drug Pricing Investigation and the Need for Structural Reforms.” on Friday, December 10, 2021, at 10 a.m. Professor Conti will discuss recently published papers germane to the current public debate on lowering prescription drug prices.